Lactoferrin for neuroprotection in term neonatal HypoxicIichemic Encephalopathy

Prof. Stéphane Sizonenko, Department of Pediatrics, Gynecology, and Obstetrics, School of Medicine, University of Geneva, Switzerland

Neonatal hypoxic-ischemic (HI) encephalopathy (HIE) in termnewborns is a leading cause of mortality and chronic disability. Hypothermia (HT) is the only clinically available therapeutic intervention; however, its neuroprotective effects are limited.

 

Study Aim

To evaluate the combination of early oral administration of lactoferrin with whole body hypothermia could enhance neuroprotection.

 

Scientific Approach

Using HIE rat model of HIE, supplemented with lactoferrin prior to HIE procedure, brain neurochemical profile and gene expressions related to glutamatergic excitotoxicity, energy metabolism and inflammation in the brain will be assessed.

 

Expected Outcomes

This study will reveal the mechanisms by which lactoferrin acts as a neuroprotector and pave the way of new neuroprotective strategies to broaden the effects of hypothermia therapy, and ultimately better treat neonatal brain hypoxic-ischemic.

Funded projects